EA201500362A1 - Ингибиторы rho-киназы - Google Patents
Ингибиторы rho-киназыInfo
- Publication number
- EA201500362A1 EA201500362A1 EA201500362A EA201500362A EA201500362A1 EA 201500362 A1 EA201500362 A1 EA 201500362A1 EA 201500362 A EA201500362 A EA 201500362A EA 201500362 A EA201500362 A EA 201500362A EA 201500362 A1 EA201500362 A1 EA 201500362A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- rho
- kinase inhibitors
- rock1
- rock2
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Abstract
Изобретение относится к ингибиторам ROCK1 и/или ROCK2. Также предложены способы лечения заболеваний и расстройств, включающие ингибирование ROCK1 и/или ROCK2.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261710373P | 2012-10-05 | 2012-10-05 | |
US201361840288P | 2013-06-27 | 2013-06-27 | |
PCT/US2013/063752 WO2014055996A2 (en) | 2012-10-05 | 2013-10-07 | Rho kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201500362A1 true EA201500362A1 (ru) | 2015-08-31 |
Family
ID=50435589
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201500362A EA201500362A1 (ru) | 2012-10-05 | 2013-10-07 | Ингибиторы rho-киназы |
Country Status (16)
Country | Link |
---|---|
US (4) | US9815820B2 (ru) |
EP (2) | EP2903618B1 (ru) |
JP (2) | JP6419076B2 (ru) |
CN (5) | CN113773308A (ru) |
CA (2) | CA2926478C (ru) |
DK (1) | DK2903618T3 (ru) |
EA (1) | EA201500362A1 (ru) |
ES (1) | ES2924915T3 (ru) |
HR (1) | HRP20220913T1 (ru) |
HU (1) | HUE059305T2 (ru) |
LT (1) | LT2903618T (ru) |
PL (1) | PL2903618T3 (ru) |
PT (1) | PT2903618T (ru) |
RS (1) | RS63503B1 (ru) |
SI (1) | SI2903618T1 (ru) |
WO (1) | WO2014055996A2 (ru) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11008359B2 (en) * | 2002-08-23 | 2021-05-18 | Illumina Cambridge Limited | Labelled nucleotides |
CN113773308A (zh) | 2012-10-05 | 2021-12-10 | 卡德门企业有限公司 | Rho激酶抑制剂 |
WO2015157556A1 (en) * | 2014-04-09 | 2015-10-15 | Kadmon Corporation, Llc | Treatment of gvhd |
EP3183248B1 (en) | 2014-08-21 | 2020-11-11 | Bristol-Myers Squibb Company | Tied-back benzamide derivatives as potent rock inhibitors |
EA036257B1 (ru) * | 2014-10-07 | 2020-10-20 | КАДМОН КОРПОРЕЙШН, ЭлЭлСи | Антитела человека против vegfr-2/kdr |
US10112935B2 (en) | 2015-02-27 | 2018-10-30 | Lycera Corporation | Indazolyl thiadiazolamines and related compounds for inhibition of Rho-associated protein kinase and the treatment of disease |
EP3283479B1 (en) * | 2015-04-01 | 2022-12-14 | Rigel Pharmaceuticals, Inc. | Tgf-beta inhibitors |
WO2016200694A1 (en) | 2015-06-10 | 2016-12-15 | Hackensack University Medical Center | Use of telmisartan to prevent and treat graft versus host disease and other alloimmune and autoimmune diseases |
EA201890153A1 (ru) * | 2015-06-26 | 2018-06-29 | КАДМОН КОРПОРЕЙШН, ЭлЭлСи | Ингибиторы поглощения глюкозы |
JP2019506863A (ja) * | 2016-02-02 | 2019-03-14 | カドモン コーポレイション,リミティド ライアビリティ カンパニー | Pd−l1及びkdrに対する二重結合タンパク質 |
BR112019002039A2 (pt) | 2016-08-05 | 2019-05-07 | Medimmune, Llc | anticorpos anti-o2 e uso dos mesmos |
EP3504204A4 (en) | 2016-08-26 | 2020-05-27 | Lycera Corporation | INDAZOLYL-L, 2,4-THIADIAZOLAMINE AND RELATED COMPOUNDS FOR INHIBITING RHO-ASSOCIATED PROTEIN KINASES AND FOR TREATING DISEASES |
AU2017346488A1 (en) | 2016-10-19 | 2019-05-30 | Humabs Biomed Sa | Anti-O1 antibodies and uses thereof |
CN106916145B (zh) * | 2017-03-06 | 2019-06-04 | 上海应用技术大学 | SLx-2119的合成方法 |
IT201700047189A1 (it) * | 2017-05-02 | 2018-11-02 | Fondazione St Italiano Tecnologia | Composti e composizioni per il trattamento di cancro, disordini della retina e cardiomiopatie |
US10329282B2 (en) | 2017-06-30 | 2019-06-25 | Beijing Tide Pharmaceutical Co., Ltd. | Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof |
AU2018294054B2 (en) | 2017-06-30 | 2022-05-26 | Beijing Tide Pharmaceutical Co., Ltd. | Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof |
US10323023B2 (en) | 2017-06-30 | 2019-06-18 | Beijing Tide Pharmaceutical Co., Ltd. | Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof |
EA202090572A1 (ru) * | 2017-09-01 | 2020-07-06 | Кадмон Корпорейшн, Ллк | ИНГИБИТОРЫ Rho-АССОЦИИРОВАННОЙ, СОДЕРЖАЩЕЙ СУПЕРСПИРАЛЬ ПРОТЕИНКИНАЗЫ |
CN111406051A (zh) | 2017-09-03 | 2020-07-10 | 安吉昂生物医药公司 | 作为rho相关卷曲螺旋激酶(rock)抑制剂的乙烯基杂环 |
WO2019201297A1 (zh) | 2018-04-18 | 2019-10-24 | 南京明德新药研发有限公司 | 作为rho激酶抑制剂的苯并吡唑类化合物 |
US11248004B2 (en) | 2018-11-06 | 2022-02-15 | Cervello Therapeutics, Llc. | Substituted isoquinolines as rock kinase inhibitors |
US10745381B2 (en) | 2018-11-06 | 2020-08-18 | Cervello Therapeutics, Llc. | Substituted isoquinolines and phthalazines as rock kinase inhibitors |
US20220202827A1 (en) * | 2019-04-08 | 2022-06-30 | The General Hospital Corporation | Enhancement of Melanocyte Migration Using ROCK Inhibitors |
EP4046686B1 (en) | 2019-10-18 | 2023-11-01 | Medshine Discovery Inc. | Salt types, crystal forms, and preparation methods for benzopyrazole compounds as rho kinase inhibitors |
WO2021129589A1 (zh) * | 2019-12-27 | 2021-07-01 | 广东东阳光药业有限公司 | Kd-025的新晶型及其制备方法 |
KR20230043910A (ko) | 2020-07-22 | 2023-03-31 | 테바 파마슈티컬스 인터내셔널 게엠베하 | 벨루모수딜 및 벨루모수딜 염의 고체 상태 형태 |
IL299985A (en) * | 2020-07-22 | 2023-03-01 | Beijing Tide Pharmaceutical Co Ltd | A method for treating graft-versus-Maschen disease caused by hematopoietic stem cell transplantation |
CN114105976B (zh) * | 2020-08-28 | 2024-04-26 | 杭州邦顺制药有限公司 | 选择性rock2激酶抑制剂 |
CA3207859A1 (en) | 2021-01-11 | 2022-07-14 | Incyte Corporation | Combination therapy comprising jak pathway inhibitor and rock inhibitor |
WO2022170864A1 (zh) * | 2021-02-09 | 2022-08-18 | 苏州科睿思制药有限公司 | Belumosudil甲磺酸盐的晶型及其制备方法和用途 |
WO2022229351A1 (en) | 2021-04-28 | 2022-11-03 | Graviton Bioscience Bv | Selective inhibitors of rock2 for the treatment of muscular dystrophy |
WO2023285706A1 (en) | 2021-07-16 | 2023-01-19 | Sandoz Ag | Solid-state forms of 2-(3-(4-(1h-indazol-5-ylamino)quinazolin-2-yl )phenoxy)-n- isopropylacetamide methane sulfonic acid salt |
TW202404602A (zh) | 2022-04-19 | 2024-02-01 | 美商凱德蒙有限責任公司 | 移植後肺部病症的治療方法 |
CA3178086A1 (en) | 2022-07-14 | 2024-01-14 | Kadmon Corporation, Llc | Methods of administering belumosudil for treatment of chronic graft versus host disease in patient subpopulations |
WO2024015066A1 (en) | 2022-07-14 | 2024-01-18 | Kadmon Corporation, Llc | Methods of administering belumosudil in combination with cyp3a inducers and/or proton pump inhibitors |
WO2024015067A1 (en) | 2022-07-14 | 2024-01-18 | Kadmon Corporation, Llc | Methods of administering belumosudil for treatment of chronic graft versus host disease |
CA3178085A1 (en) | 2022-07-14 | 2024-01-14 | Kadmon Corporation, Llc | Belumosudil metabolites and uses thereof in the treatment of chronic graft-versus-host disease |
WO2024023276A1 (en) | 2022-07-27 | 2024-02-01 | Graviton Bioscience Bv | Rock2 inhibitors for the treatment of viral infections |
WO2024063770A1 (en) | 2022-09-21 | 2024-03-28 | Kadmon Corporation, Llc | Liquid formulation of belumosudil |
CN117243959A (zh) * | 2022-10-13 | 2023-12-19 | 山东大学 | 治疗骨质疏松的方法和药物组合物 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59115488A (ja) * | 1982-12-22 | 1984-07-03 | Hitachi Ltd | 密閉形スクロ−ル圧縮機の軸受装置 |
JP4469179B2 (ja) | 2002-01-23 | 2010-05-26 | バイエル ファーマセチカル コーポレーション | Rhoキナーゼ阻害剤としてのピリミジン誘導体 |
EP1781293A1 (en) | 2004-06-04 | 2007-05-09 | Amphora Discovery Corporation | Quinoline- and isoquinoline-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
CR9465A (es) * | 2005-03-25 | 2008-06-19 | Surface Logix Inc | Compuestos mejorados farmacocineticamente |
US8216575B2 (en) | 2006-03-31 | 2012-07-10 | Chengdu Kanghong Biotechnologies Co., Ltd. | Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains |
WO2008054599A2 (en) * | 2006-09-27 | 2008-05-08 | Surface Logix, Inc. | Rho kinase inhibitors |
US8648069B2 (en) | 2007-06-08 | 2014-02-11 | Abbvie Inc. | 5-substituted indazoles as kinase inhibitors |
AU2009257635A1 (en) | 2008-06-10 | 2009-12-17 | Plexxikon, Inc. | 5H-Pyrrolo [2,3-b] pyrazine derivatives for kinase modulation, and indications therefor |
AU2010322287B2 (en) | 2009-11-17 | 2014-04-03 | The Regents Of The University Of Michigan | 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties |
EA031616B1 (ru) * | 2010-03-02 | 2019-01-31 | пиЭйч ФАРМА Ко., ЛТД. | Новые ингибиторы rock |
US9079880B2 (en) * | 2010-07-07 | 2015-07-14 | Boehringer Ingelheim International Gmbh | Rho kinase inhibitors |
WO2012040499A2 (en) * | 2010-09-22 | 2012-03-29 | Surface Logix, Inc. | Metabolic inhibitors |
CN103313968A (zh) | 2010-11-15 | 2013-09-18 | Abbvie公司 | Nampt和rock抑制剂 |
GB201107223D0 (en) | 2011-04-29 | 2011-06-15 | Amakem Nv | Novel rock inhibitors |
GB201114854D0 (en) | 2011-08-29 | 2011-10-12 | Amakem Nv | Novel rock inhibitors |
MX2014002394A (es) | 2011-08-31 | 2014-06-05 | Amakem Nv | Inhibidores de rock suaves, novedosos. |
US20150238601A1 (en) * | 2012-10-05 | 2015-08-27 | Kadmon Corporation, Llc | Treatment of ocular disorders |
CN113773308A (zh) * | 2012-10-05 | 2021-12-10 | 卡德门企业有限公司 | Rho激酶抑制剂 |
WO2015157556A1 (en) * | 2014-04-09 | 2015-10-15 | Kadmon Corporation, Llc | Treatment of gvhd |
-
2013
- 2013-10-07 CN CN202110707631.7A patent/CN113773308A/zh active Pending
- 2013-10-07 CN CN202110707587.XA patent/CN113637008A/zh active Pending
- 2013-10-07 LT LTEPPCT/US2013/063752T patent/LT2903618T/lt unknown
- 2013-10-07 ES ES13843426T patent/ES2924915T3/es active Active
- 2013-10-07 EA EA201500362A patent/EA201500362A1/ru unknown
- 2013-10-07 JP JP2015535880A patent/JP6419076B2/ja active Active
- 2013-10-07 CA CA2926478A patent/CA2926478C/en active Active
- 2013-10-07 EP EP13843426.1A patent/EP2903618B1/en active Active
- 2013-10-07 SI SI201332003T patent/SI2903618T1/sl unknown
- 2013-10-07 PL PL13843426.1T patent/PL2903618T3/pl unknown
- 2013-10-07 CN CN201380063599.7A patent/CN105120869A/zh active Pending
- 2013-10-07 RS RS20220776A patent/RS63503B1/sr unknown
- 2013-10-07 EP EP22175888.1A patent/EP4116293A3/en active Pending
- 2013-10-07 HU HUE13843426A patent/HUE059305T2/hu unknown
- 2013-10-07 US US14/431,936 patent/US9815820B2/en active Active
- 2013-10-07 CA CA3151343A patent/CA3151343A1/en active Pending
- 2013-10-07 DK DK13843426.1T patent/DK2903618T3/da active
- 2013-10-07 WO PCT/US2013/063752 patent/WO2014055996A2/en active Application Filing
- 2013-10-07 PT PT138434261T patent/PT2903618T/pt unknown
- 2013-10-07 CN CN202110707706.1A patent/CN113620933A/zh active Pending
- 2013-10-07 CN CN202110707555.XA patent/CN113637007A/zh active Pending
- 2013-10-07 HR HRP20220913TT patent/HRP20220913T1/hr unknown
-
2017
- 2017-11-10 US US15/809,460 patent/US10183931B2/en active Active
-
2018
- 2018-10-09 JP JP2018191181A patent/JP6703075B2/ja active Active
-
2019
- 2019-01-18 US US16/251,952 patent/US10696660B2/en active Active
-
2020
- 2020-06-26 US US16/913,267 patent/US20210147391A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201500362A1 (ru) | Ингибиторы rho-киназы | |
CY1124311T1 (el) | Παρεμποδιστες dna-pk | |
AU2018236800B2 (en) | DNA-PK inhibitors | |
EA201390711A1 (ru) | Гидроксиамидные соединения пиримидина в качестве ингибиторов деацетилаз белков и способы их применения | |
EA201591591A1 (ru) | Соединения карбазола, применяемые в качестве ингибиторов бромодомена | |
EA201390609A1 (ru) | ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ | |
MY165620A (en) | Cyclopropylamines as lsd1 inhibitors | |
MX362550B (es) | Inhibidores ciclicos de glutaminasa. | |
MX2015004771A (es) | Metodos para tratar cancer. | |
MX2013015158A (es) | Compuestos inhibidores de metaloenzima. | |
TR201819092T4 (tr) | Serin proteaz inhibitörleri olarak multi-sübstüte edilmiş aromatik bileşikler. | |
EA201200473A1 (ru) | Замещенные (гетероарилметил)тиогидантоины | |
EA201170531A1 (ru) | Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака | |
EA201591360A1 (ru) | Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств | |
EA201691032A1 (ru) | Производные изохромена в качестве ингибиторов фосфоинозитид-3-киназ | |
EA201692313A1 (ru) | Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ | |
EA201690039A1 (ru) | Ингибиторы rorc2 и способы их применения | |
TN2015000120A1 (en) | Oxazolidin-2-one-pyrimidine derivatives | |
EA201690783A1 (ru) | Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний | |
EA201690227A1 (ru) | Азаиндольные соединения, их получение и способы их применения | |
MX2015007945A (es) | Usos y métodos para el tratamiento de enfermedades o afecciones hepáticas. | |
UA115052C2 (uk) | Конденсоване біциклічне 2,4-діамінопіримідинове похідне як подвійний alk- i fak-інгібітор | |
EA201400970A1 (ru) | Новые композиции для лечения амиотрофического бокового склероза | |
UA109932C2 (xx) | Циклопропіламіни як інгібітори lsd1 | |
MX2015009678A (es) | Compuestos de pirimidina condensada sustituida con amino en la posicion 4 como inhibidores de fosfodiesterasa 4 (pde4). |